Amgen's Q3 earnings call revealed a mixed bag of results, with the company achieving record sales but facing challenges in its anemia franchise due to labeling and reimbursement changes. Despite this, management expressed optimism about the company's long-term prospects, driven by growth in non-anemia products such as ENBREL and Vectibix, as well as a robust pipeline of new products. The company also announced progress in its restructuring efforts, aimed at reducing costs and improving efficiency. Overall, while Amgen faces short-term headwinds, its strong pipeline and cost-cutting measures position it well for long-term success. 
[1]